drugset / Trial / NCT00619697

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes

NCT00619697

Phase 4 Completed 260 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.

Timeline

Start
2003-12
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule
Subject Metformin Small molecule
Subject biphasic insulin aspart Protein / enzyme biologic 0.4 iu/kg
Subject insulin glargine Protein / enzyme biologic 0.39 iu/kg